TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this medical technology company would post a loss of $0.05 per share when it actually produced earnings of $0.35, delivering a surprise of 800%. Over the last four quarters, the ...

Exhibit 99.1 TransMedics Reports Second Quarter 2024 Financial Results Andover, Mass. – July 31, 2024 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights ▪ Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023 ▪ Generat ...

ANDOVER, Mass., July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $114.3 million in the second quarter of 2024, a 118% increase compared to the second quarter of 2023 Generated net income of $12.2 million or $0.35 per diluted share in t ...

ANDOVER, Mass., July 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 13, 2024, at 9:30 a.m. Eastern Standard Time. Event: Ca ...

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock. Analysts on Wall Street project that TransMedics (TMDX) will announce quarterly earnings of $0.21 per share in its forthcomin ...

ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. TransMedics is the world's lea ...

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Therefore, the Zacks rating upgrade for TransMedics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as reflected i ...

Viking Therapeutics (VKTX 7.13%) doesn't have an approved product on the market yet. However, its market cap of around $5.2 billion underscores investors' excitement about Viking's pipeline. Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years. 1. Vertex Pharmaceuticals I predict that Vertex will add three other blockbuster drugs that don't treat CF to its lineup by 2030. It seems likely to win U.S. approval of su ...

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20- day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. The ...

Brian Johnston 332-895-3222 [email protected] SOURCE TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the tr ...